Year in Review: Updates in Antibody-Drug Conjugates for Treating Advanced NSCLC - Episode 1

Molecular Testing in Advanced NSCLC

,

Benjamin Levy, MD, discusses the role of molecular testing in patients with advanced NSCLC.

Now Viewing
EP. 1: Molecular Testing in Advanced NSCLC
EP. 2: T-DXd in HER2 Mutated Advanced NSCLC
EP. 3: Dato-DXd for Treating Advanced NSCLC
EP. 4: Sacituzumab Govitecan + Pembrolizumab in First-Line Metastatic NSCLC
EP. 5: Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC
EP. 6: Future Perspectives in ADCs for Treating Advanced NSCLC
EP. 7: Tackling All Questions ADC: How These Agents Are Joining a Treatment Revolution in NSCLC
EP. 8: Increasingly Targeted ADCs Drive NSCLC Treatment Innovations

Related Content:

Year in Review: Updates in Antibody-Drug Conjugates for Treating Advanced NSCLCLung CancerInsightsInsights Video Series
Single-Agent Immune Therapy in UC: The Need for More
Outlining the Current First-Line Treatment Landscape in Metastatic Urothelial Cancer: Starting With a Cisplatin-Ineligible Patient Case
Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation